PMCID,sentence_id,text,CONSORT_item,Prediction
PMC3266479,S37,"we undertook a multicentre, pragmatic, double-blind, placebo-controlled, parallel-group, randomised trial at 46 uk intensive-care units between december, 2006, and march, 2010.","['4b', '3a']","['3a', '4b']"
PMC3266479,S38,eligible participants were intubated and mechanically ventilated adults aged 16 years and older within 72 h of ards onset.,['4a'],['4a']
PMC3266479,S39,patients were identified and recruited by local investigators at each site.,['0'],[]
PMC3266479,S40,"we defined ards in accordance with the american european consensus criteria:14 a pressure of arterial oxygen to fractional inspired oxygen concentration (pao2/fio2) ratio of 200 mm hg or less, bilateral pulmonary infiltrates consistent with oedema, and the absence of clinically evident left atrial hypertension.",['4a'],[]
PMC3266479,S41,"exclusion criteria were pregnancy; current treatment with intravenous β-2 agonist or need for continuous, regular, aerolised β-2 agonists; current treatment with β-adrenergic antagonists; imminent withdrawal of medical treatment; chronic liver disease, defined as child-pugh grade c; and enrolment in another clinical trial of an investigational medicinal product within the previous 28 days.",['4a'],['4a']
PMC3266479,S42,"sedated patients did not have capacity to give consent; therefore, consistent with requirements of the eu clinical trial directive,15 we obtained written informed consent from a personal or professional legal representative before randomisation.",['0'],[]
PMC3266479,S43,all surviving patients were informed about the trial at the earliest opportunity after regaining competence and consent to continue in the trial was sought.,['0'],[]
PMC3266479,S44,the study protocol16 was approved for all centres by the oxfordshire research ethics committee a.,['0'],[]
PMC3266479,S45,site specific approval was obtained at each site.,['0'],[]
PMC3266479,S46,the trial was monitored for safety by an independent data monitoring and ethics committee.,['0'],[]
PMC3266479,S48,"study drug packs were prepared by bilcare global clinical supplies (europe; powys, uk).",['0'],[]
PMC3266479,S49,"the active and placebo drug components of the infusions were packaged identically into numbered treatment packs, each containing 5 ml of either salbutamol sulphate bp (1 mg/ml in a sterile isotonic solution, glaxosmithkline, middlesex, uk) or placebo (0·9% sterile sodium chloride).","['9', '5']",['9']
PMC3266479,S50,we used a computer-generated randomisation sequence with a block size of eight.,"['8b', '8a']",['8a']
PMC3266479,S51,"patients were randomly assigned in a 1:1 ratio by a centralised 24 h telephone or web-based randomisation service (university of aberdeen, uk).",['10'],['10']
PMC3266479,S52,"randomisation was minimised by centre, pao2/fio2 ratio (≤50, 51–99, or ≥100 mm hg), and age (<64, 65–84, ≥85 years).",['8b'],['8b']
PMC3266479,S53,"participants, care providers, and investigators were masked to group assignment.",['11a'],['11a']
PMC3266479,S55,"we obtained acute physiology and chronic health evaluation ii (apache ii) scores from intensive care national audit and research centre (icnarc) for sites (n=36) that participate in the icnarc's case mix programme or, for non-participating sites (ten), we obtained data necessary for calculation of the scores.",['6a'],[]
PMC3266479,S56,"we used the apache ii score to calculate the mortality risk, which we used for subgroup analysis.",['6a'],['12b']
PMC3266479,S57,"the most likely cause of ards was identified by the treating clinician and categorised as direct lung injury (smoke or toxin inhalation, aspiration of gastric content, near drowning, thoracic trauma, pneumonia, or other) or indirect lung injury (sepsis, cardiopulmonary bypass, pancreatitis, non-thoracic trauma, other).",['6a'],[]
PMC3266479,S58,"the protocol recommended use of a lung protective ventilation strategy on the basis of ideal bodyweight,17 fluid restriction,18 and appropriate high positive end-expiratory pressure.19",['0'],['5']
PMC3266479,S59,compliance with recommendations for protective ventilation were assessed at baseline only (tidal volumes per kg ideal bodyweight).,['6a'],[]
PMC3266479,S60,all other treatments were delivered in accordance with local clinical practice.,['6a'],['5']
PMC3266479,S61,"before the start of recruitment, the intensive-care unit nurse was trained to monitor side-effects of the treatment and to inform the research team as necessary.",['6a'],[]
PMC3266479,S62,infusion syringes were prepared immediately before use by the nurse and contained two ampoules of the blinded solutions (salbutamol or placebo) diluted with 40 ml of saline in a 50 ml syringe.,['6a'],"['5', '9']"
PMC3266479,S63,salbutamol and placebo were administered through a dedicated intravenous line at a rate of 0·075 ml/kg ideal bodyweight per h (equivalent to 15 μg salbutamol per kg ideal bodyweight per h).,['6a'],['5']
PMC3266479,S64,"the patient was measured from heel to vertex with a soft tape measure, and the ideal bodyweight and infusion rate obtained from the conversion table.17",['6a'],['6a']
PMC3266479,S65,"if any patient developed a tachycardia (heat rate >140 beats per min), new arrhythmia, or lactic acidosis, we adjusted the infusion rate according to a prespecified dose-adjustment schedule.15",['6a'],['5']
PMC3266479,S66,"infusion of the study drug was stopped at 7 days, or earlier if clinically indicated.",['6a'],['5']
PMC3266479,S68,"the primary outcome was 28-day mortality, defined as death up to the end of calendar day 28 after randomisation.",['6a'],['6a']
PMC3266479,S69,"secondary outcomes were mortality in the intensive-care unit or hospital before first discharge; ventilator-free and organ failure-free days from randomisation to day 28; length of stay in intensive-care unit and hospital; and tachycardia, new arrhythmia, or other side-effects sufficient to stop treatment with trial drug.",['6a'],['6a']
PMC3266479,S70,we defined ventilator-free days as the number of calendar days after patients started unassisted breathing until day 28 after randomisation for patients who survived at least 48 consecutive hours after start of unassisted breathing.20,['6a'],['6a']
PMC3266479,S71,the number of ventilator-free days was zero for patients who died without start of unassisted breathing or before 48 consecutive hours of unassisted breathing.20,['6a'],[]
PMC3266479,S72,"we defined organ failure-free days as the number of days in the first 28 days after randomisation that the patient received no cardiovascular, renal, liver, or neurological support as defined by the critical care minimum dataset.21",['6a'],['6a']
PMC3266479,S73,"we did not plan to collect data for cause of death in the original trial protocol; however, after early termination of the trial because of the increased 28-day mortality in the salbutamol group, the data for the main cause of death were ascertained for all participants dying within 28 days of randomisation.",['6b'],[]
PMC3266479,S74,we requested causes of death as recorded on the death certificate for the disorder directly leading to death.,['6b'],['6a']
PMC3266479,S75,"patients who remained alive and in critical care after randomisation were monitored daily until discharged to a ward, or until day 28.",['6a'],['5']
PMC3266479,S77,we based the sample-size calculation on our balti trial13 and on 2005 data from the intensive care national audit and research centre.,['7a'],['7a']
PMC3266479,S78,"the target sample size of 1334 gave 90% power at p<0·05 to detect a risk ratio (rr) of 0·8 for 28-day mortality between the salbutamol and placebo groups with a 3% loss of patients for the primary outcome, with the assumption that the 28-day mortality in the placebo group was 44%.",['7a'],['7a']
PMC3266479,S79,"we planned interim analyses every 12 months, or more frequently if requested by the data monitoring and ethics committee.",['7b'],['7b']
PMC3266479,S80,the committee used the haybittle-peto22 stopping guideline: a difference of three standard errors would be needed before considering recommending trial cessation for benefit at an interim analysis.,['7b'],['7b']
PMC3266479,S81,all analyses were based on intention-to-treat analyses.,['0'],[]
PMC3266479,S82,we compared the primary outcome and other dichotomous outcomes using rrs and 95% cis.,['12a'],['12a']
PMC3266479,S83,we compared continuous outcomes with mean differences and their 95% cis.,['12a'],['12a']
PMC3266479,S84,"we analysed 28-day mortality with survival analysis, and by comparison of the two groups with hazard ratios and 95% cis and the kaplan–meier curve.",['12a'],['12a']
PMC3266479,S85,all reported p values are two-sided and were not adjusted for multiple comparisons.,['12a'],['12a']
PMC3266479,S86,"we used prespecified subgroup analyses to investigate the effects of age, severity of hypoxaemia at study entry, cause (direct vs indirect causes of ards), and the apache ii mortality risk, on the effect of salbutamol.",['12b'],['12b']
PMC3266479,S87,"all subgroup analyses used interaction tests; we either calculated the ratio of rrs between the subgroups, or used interaction terms in logistic regression models.",['12b'],"['12a', '12b']"
PMC3266479,S88,we did a post-hoc analysis for the main causes of death as recorded on the death certificates of participants who died within 28 days of randomisation.,['12b'],['12b']
PMC3266479,S89,"this trial is registered, isrctn38366450 and eudract number 2006-002647-86.",['0'],[]
PMC3266479,S91,"the sponsor of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report.",['0'],[]
PMC3266479,S92,"fgs, sg, gdp, and sel had full access to all the data in the study, and the corresponding author had final responsibility for the decision to submit for publication.",['0'],[]
PMC4893154,S27,vindicate was a randomized placebo-controlled double-blind trial of vitamin d supplementation in vitamin d−deficient chronic hf patients on optimal medical therapy.,['3a'],['3a']
PMC4893154,S28,"patients were eligible if they had stable (>3 months) new york heart association functional class ii or iii symptoms, a left ventricular ejection fraction (lvef) ≤45% on maximally tolerated medical therapy (>3 months) and a 25(oh) vitamin d level of <50 nmol/l (<20 ng/ml).",['4a'],['4a']
PMC4893154,S29,"patients were ineligible if they were taking or had taken calcium or other vitamin supplements in the last 3 months; if their chronic hf was due to untreated valvular heart disease, anemia or thyrotoxicosis; if they had existing indications for vitamin d supplementation (e.g., previous osteoporotic fracture or symptoms of osteomalacia); if they had a history of primary hyperparathyroidism, sarcoidosis, tuberculosis or lymphoma, a cholecalciferol concentration at the time of screening >50 nmol/l (20 ng/ml); or if there was significant renal dysfunction (estimated glomerular filtration rate <30 ml/min).",['4a'],['4a']
PMC4893154,S31,"patients enrolled into vindicate were allocated in blocks of 20 using minimization balancing for etiology of chronic hf (ischemic/non-ischemic), diabetes mellitus, sex, chronic obstructive pulmonary disease (requiring use of regular bronchodilators), and ethnic origin (caucasian/non-caucasian).","['8b', '8a']","['10', '8a', '8b']"
PMC4893154,S32,"each participant was asked to take 2 tablets per day providing either a total of 100 μg cholecalciferol (4,000 iu daily) or placebo (cultech, port talbot, wales, united kingdom).",['5'],['5']
PMC4893154,S33,the supplement and dose were chosen based upon guidelines for studies of vitamin d supplementation (17).,['5'],['5']
PMC4893154,S34,"these guidelines suggest that studies should: 1) aim to replace physiological requirements, supplementing between 75 and 250 μg/day; 2) last at least 9 months; 3) supplement with vitamin d3 (not d2); 4) assay supplements for potency; 5) include a regular serum measurement of 25(oh)d3 levels; and 6) aim to achieve serum levels in patients on active therapy between 100 and 160 nmol/l (40 ng/ml to 64 ng/ml).",['0'],['5']
PMC4893154,S35,"also, on the basis of recent data demonstrating the adverse effect of hyperparathyroidism in chronic hf (18), we chose a dose likely to suppress parathyroid hormone (pth) release.",['5'],['5']
PMC4893154,S36,"our proof of concept study, using the same inclusion and exclusion criteria and protocol as vindicate, had previously demonstrated the efficacy of 4,000 iu daily to achieve positive remodeling with significant reductions in left ventricular end-diastolic volume (lvedv), left ventricular end-systolic volume (lvesv), and left ventricular end-diastolic dimension (lvedd).",['0'],[]
PMC4893154,S37,"the consort diagram and results from this study are presented in online supplementary datasets (online figure 1, online tables 1 and 2).",['0'],[]
PMC4893154,S38,"a simple linear model-based trend test from this study demonstrated a significant decrease in pth over the year (p = 0.0095) in those allocated vitamin d, with no such trend in patients allocated to the placebo arm (p = 0.977) (online figure 2) (19).",['0'],[]
PMC4893154,S40,the pre-specified primary endpoint in vindicate was the difference in change in 6-min walk test distance (6mwt) (baseline to 12 months) between the 2 groups.,['6a'],['6a']
PMC4893154,S41,"key pre-specified secondary endpoints included cardiac structure and function, and safety endpoints of serum calcium concentration, renal function, and vitamin d levels. hypervitaminosis d was defined as 25(oh)d3 >200 nmol/l (80 ng/ml), and hypercalcemia as >2.6 nmol/l (10.4 mg/dl).",['6a'],['6a']
PMC4893154,S43,at baseline each patient performed a 6mwt according to standard criteria (20).,['6a'],[]
PMC4893154,S44,"each patient also underwent echocardiography and blood sampling for serum calcium, serum creatinine, vitamin d, and pth levels.",['6a'],['6a']
PMC4893154,S45,patients were also invited to undergo cardiac magnetic resonance (cmr) imaging to measure lv volumes.,['6a'],[]
PMC4893154,S46,"subsequent visits took place at 3, 6, 9, and 12 months and blood draws were repeated at each visit for safety data.",['6a'],['6a']
PMC4893154,S48,serum 25(oh)d2 and 25(oh)d3 were analyzed by tandem mass spectrometry.,['6a'],['6a']
PMC4893154,S49,samples were prepared using a protein precipitation reagent containing deuterated cholecalciferol.,['6a'],['6a']
PMC4893154,S50,"the supernatant was analyzed on an api5000 lc-ms/ms (ab sciex, warrington, united kingdom) in atmospheric-pressure chemical ionization mode.",['6a'],['6a']
PMC4893154,S51,the inter-assay coefficient of variability was <10% at all concentrations ranging from 12 nmol/l to 159 nmol/l (4.8 ng/ml to 63.7 ng/ml).,['6a'],['6a']
PMC4893154,S52,"ergocalciferol and cholecalciferol concentrations were summed and reported as total 25(oh)d. we defined deficiency and insufficiency of vitamin d concentrations as <50 nmol/l (20 ng/ml) and <75 nmol/l (30 ng/ml), respectively 21, 22.",['6a'],['6a']
PMC4893154,S53,"we also measured serum calcium, creatinine, and pth (siemens advia and centaur, siemens healthcare diagnostics, camberley, united kingdom).",['6a'],['6a']
PMC4893154,S54,"to confirm effective conversion of the supplement, we also measured 1,25(oh)d3 by radioimmunoassay (ids, boldon, united kingdom) at baseline and 12 months.",['6a'],['6a']
PMC4893154,S56,echocardiography was performed on all patients at baseline and lv function was assessed according to european society of cardiology criteria using simpson’s biplane measure to determine lvef (23).,['6a'],['6a']
PMC4893154,S57,echocardiography was repeated at 12 months.,['6a'],['6a']
PMC4893154,S58,echocardiograms at both time points were analyzed offline at the end of the study by 2 senior echocardiographers blinded to patient treatment.,['6a'],['6a']
PMC4893154,S60,"cmr studies were performed on dedicated 1.5-t or 3-t cmr systems (philips healthcare, best, the netherlands).",['6a'],[]
PMC4893154,S61,the same system was used for baseline and follow-up studies (at 12 months) of individual patients.,['6a'],[]
PMC4893154,S62,"a multislice multiphase data set covering the entire left ventricle in 10 to 12 short axis slices was acquired using a validated 2-dimensional balanced steady-state free precession pulse sequence (tr 2.8 ms, te 1.4 ms, flip angle 55°, spatial resolution 2.0 mm × 2.0 mm × 10 mm, no interslice gap, 30 phases/cardiac cycle, 1 slice per breath-hold).",['6a'],['6a']
PMC4893154,S63,"offline analysis by an experienced cmr observer using qmass v7.0 software (medis, leiden, the netherlands) blinded to study allocation derived end-diastolic and end-systolic lv volumes and lvef.",['6a'],['6a']
PMC4893154,S65,vindicate was powered to provide information on the patient-oriented outcome of 6mwt.,['7a'],[]
PMC4893154,S66,a trial of iron supplementation in a similar patient group had demonstrated that improvements of 30 m to 40 m could be expected with this type of intervention (24).,['7a'],[]
PMC4893154,S67,"we assumed, based upon our preliminary data from a pilot study (19), that there would be a change between the 2 groups at 12 months of 30 m.",['7a'],['7a']
PMC4893154,S68,the sd of change in 6mwt was estimated from these data; the upper limit of the 80% confidence interval (ci) (estimated using bootstrapping) was used in these calculations to allow for the small sample size in the proof of concept.,['7a'],['12a']
PMC4893154,S69,this determined that 210 patients were required to have 90% power to show a difference in change in 6mwt of 28 m or more with 5% significance (sd = 62).,['7a'],['7a']
PMC4893154,S70,we aimed to recruit 230 patients (115 per group) to allow for ∼10% dropout.,['7a'],['7a']
PMC4893154,S72,differences in baseline variables between allocations were tested using student t tests (continuous data) or the chi-square test (categorical data).,['12a'],['12a']
PMC4893154,S73,"the analysis of primacy for the main efficacy endpoints was based on analysis of covariance linear models relating differences in the final walk distance and imaging variables by treatment allocation, adjusting for baselines values and reported with 95% cis (25).",['12a'],['12a']
PMC4893154,S74,all significance tests were 2-sided and called significant at the 5% level.,['12a'],['12a']
PMC4893154,S75,"all analyses were conducted in stata (version 14, statacorp., college station, texas).",['12a'],['12a']
PMC4893154,S77,a single unblinded observer with no involvement in the patients’ care or study follow-up (j.h.b.) reviewed each vitamin d result at each time point for safety.,['11a'],"['11a', '6a']"
PMC4893154,S78,an agreed operating procedure for any subject who developed a serum vitamin d concentration >200 nmol/l (80 ng/ml) involved reducing the dose of treatment from 2 to 1 tablets per day to maintain patient blinding.,['11a'],['5']
PMC4515982,S40,the trial was coordinated by the als centre at the irccs foundation ‘carlo besta’ of milan.,['0'],[]
PMC4515982,S41,consecutive patients were screened for eligibility at all the 25 italian als centres.,['4b'],"['4a', '4b']"
PMC4515982,S42,"patients aged 18–75 years and diagnosed with probable laboratory-supported, probable or definite als according to el escorial revised criteria were eligible.",['4a'],['4a']
PMC4515982,S43,inclusion criteria were onset of weakness ≤18 months and slow vital capacity (svc) ≥70% of predicted in seated position at screening visit.,['4a'],['4a']
PMC4515982,S44,"exclusion criteria were haematocrit >51% in men and >49% in women, haemoglobin value >17 g/dl; non-invasive ventilation (niv) >6 h daily; known familial als or first-degree relative with als; diagnosis of frontotemporal dementia; history and/or instrumental evidence of previous thrombotic vascular event or cardiac diseases; uncontrolled hypertension (systolic ≥160 mm hg and diastolic ≥95 mm hg irrespective of treatments at two consecutive evaluations); active solid or myeloproliferative malignancy; known hypercoagulable disorders.",['4a'],['4a']
PMC4515982,S45,all patients were asked to continue riluzole 100 mg daily or to be on a stable dose for at least 30 days prior to screening.,['0'],['5']
PMC4515982,S46,"patients who did not take riluzole at the screening visit were considered eligible and could be randomized; in this case, they could not start riluzole during the entire study period.",['4a'],['4a']
PMC4515982,S47,the protocol was approved by the ethics committee at each site.,['0'],[]
PMC4515982,S48,all patients provided written informed consent before any study-related procedure.,['0'],[]
PMC4515982,S50,"the primary outcome was one single composite outcome of time from randomisation to death, tracheotomy or >23 h niv daily for 14 consecutive days.",['6a'],['6a']
PMC4515982,S51,"secondary outcomes were changed from baseline in the alsfrs-r score, svc in the seated position and patients’ quality of life measured by the alsaq-40 questionnaire.",['6a'],['6a']
PMC4515982,S52,tolerability was evaluated analysing adverse events (aes) causing withdrawal.,['6a'],['6a']
PMC4515982,S54,patients were randomly assigned to receive either intravenous rhepo 40 000 iu or matching placebo (1:1 ratio) fortnightly for 12 months.,['5'],['5']
PMC4515982,S55,"randomisation was stratified by centre, disease severity (alsfrs-r ≤33 vs >33) and onset (spinal or bulbar), with a block size of four within each centre.",['8b'],['8b']
PMC4515982,S56,"the neuroepidemiology unit at the coordinating centre, independent of the study, generated the computer-based randomisation sequence known only to two staff persons and the drug dispenser.","['8a', '9', '10']","['10', '8a']"
PMC4515982,S57,"treatment was allocated by a web-based randomisation system, available 24 h a day.",['10'],"['10', '8a']"
PMC4515982,S58,the procedure incorporated eligibility checks according to protocol and was performed on request from the centres.,['0'],[]
PMC4515982,S59,the sequence was always available for emergency unmasking.,['0'],[]
PMC4515982,S61,"rhepo (eprex) was purchased from janssen-cilag spa (cologno monzese, italy) by the coordinating centre and directly shipped to the company (pierrel research imp srl, cantù, italy) in charge of preparing the investigational drug (rhepo or 1 cc of saline) in syringes of identical appearance, sealed in sequentially numbered identical containers according to the allocation sequence.",['11b'],['9']
PMC4515982,S62,shipping was performed for each patient within 1 week after randomisation using a refrigerated express carrier.,['5'],['5']
PMC4515982,S63,each centre stored the investigational drug at −4°c.,['5'],[]
PMC4515982,S64,"patients, neurologists, laboratory biologists/technicians (two at each centre) and a statistician were masked to treatment allocation and did not have access to any data related to rhepo haematopoietic activity.",['11a'],['11a']
PMC4515982,S65,"briefly, all participating centres generated a specific access code for the blood withdrawals of patients with als enrolled in the epos trial.",['0'],['10']
PMC4515982,S66,"at each treatment visit, the local laboratory unit received the de-identified vial reporting the randomisation number before treatment administration.",['0'],['10']
PMC4515982,S67,blood parameters were emailed to the coordinating unit where a trained person readily alerted the treating neurologist on the decision to administer or delay the treatment based on safety protocol parameters (see below).,['0'],['10']
PMC4515982,S68,"patients and treating neurologists did not have access to any data on blood parameters, whereas laboratory personnel did not have access to any data allowing the identification of the patient.",['11a'],[]
PMC4515982,S69,this procedure was elaborated to maintain the blindness of the study.,['0'],[]
PMC4515982,S70,"finally, when we designed the study, we reasoned that patients treated with rhepo could have had a higher risk of treatment delay as defined by the safety protocol.",['0'],[]
PMC4515982,S71,"therefore, the randomisation centre generated a list of placebo patients randomly assigned to 1 week treatment delay balanced with the number of patients allocated on rhepo treatment needing true delay at each centre.",['11a'],['7a']
PMC4515982,S72,this procedure was elaborated to maintain the blindness of the study.,['0'],[]
PMC4515982,S74,"after giving informed written consent, eligible patients underwent haematological examinations (haemochromocytometry, renal and liver function, serum iron, ferritin, transferrin, reticulocyte count, coagulation tests), blood pressure and body mass index (bmi) measurement and svc, alsfr-r and alsq40 assessment.",['6a'],[]
PMC4515982,S75,randomisation was performed within 15 days after the screening visit.,['0'],[]
PMC4515982,S76,"at each fortnightly treatment visit, safety parameters (haematocrit >51% in men and >49% in women or haemoglobin value >17 g/dl and value raised >1 g/dl at the end of the interval between two subsequent doses), blood pressure and bmi were assessed.",['6a'],['6a']
PMC4515982,S77,"symptoms of nocturnal hypoventilation (nocturnal arousals, morning headache, excessive daytime sleepiness, vivid dreams), medications and ae were actively monitored and recorded.",['6a'],[]
PMC4515982,S78,alsfr-r and svc were assessed monthly.,['6a'],[]
PMC4515982,S79,"at the 6-month and study end or dropout visit, the patient also underwent complete haematological examinations and alsaq-40 assessment.",['6a'],['6a']
PMC4515982,S80,"at each treatment visit, treatment administration was allowed or delayed for 1 week by the trial coordinating office after assessment of safety parameters.",['5'],['5']
PMC4515982,S81,"if treatment was delayed, the following week safety parameters were repeated before drug administration.",['5'],['5']
PMC4515982,S82,the delay of treatment administration for more than two times caused the dropout of the patient.,['0'],[]
PMC4515982,S83,"after the study end at month 12, patients underwent monthly follow-up visits for a further 6 months to record primary outcome events.",['6a'],['6a']
PMC4515982,S84,"all centres were provided with a spirometer (spirobank g multifunction, medisan srl, milano, italy) and disposable tubes for svc assessment, and trained in its use.",['6a'],[]
PMC4515982,S85,"all data were recorded by an electronic case record form specifically developed (nubilaria srl, novara, italy).",['0'],['6a']
PMC4515982,S86,"trial monitoring was performed by an independent contract research organisation (crom srl, verona, italy) that assured consistency in measuring outcomes across centres by scheduled site visits.",['0'],[]
PMC4515982,S88,nutritional status and ventilation could affect survival and thus the primary outcome of the trial.,['0'],[]
PMC4515982,S89,"during the first investigator meeting held in milan on 6 june 2010, all participating centres agreed on the approach to cotreatments, sharing the opinion that the ultimate decision would be personal to each patient.",['0'],[]
PMC4515982,S90,"we agreed that percutaneous endoscopic gastrostomy or an equivalent device should be proposed to all patients in the case of score 1 or 2 at item 3 of the alsfrs-r, unintentional loss of body weight >10% in the past 3 months or choking during food, liquids or medication ingestion.",['5'],['5']
PMC4515982,S91,"niv should be proposed to all patients in the case of score 0 or 1 at item 10 or 11 of the alsfrs-r, svc<50% or abnormal nocturnal oximetry (sao2 <90% for 4% of the overnight recorded time).",['5'],['5']
PMC4515982,S93,"on the basis of the results of our pilot study (ie, observed rates of 0.56 for death and 0.33 for tracheotomy at 18 months in the placebo group),13 we estimated that we would need a sample size of 203 patients followed up for 12 months to give 97% power to detect a significant difference between rhepo and placebo corresponding to a 67% relative reduction of risk of death and 74% power to detect a 70% relative reduction of risk of respiratory events (tracheotomy or >23 h niv), with a two-sided type 1 error of 5% and given an anticipated dropout rate of 10%.",['7a'],['7a']
PMC4515982,S95,the main analysis of primary and secondary outcomes included all randomised patients who took at least one dose of the investigational drug in their original assigned groups.,['0'],[]
PMC4515982,S96,all analyses were performed both for the entire population and for the subgroups of patients with alsfrs-r ≥33 or <3314 and with spinal or bulbar onset at randomisation.,['0'],['12b']
PMC4515982,S97,a per-protocol analysis was carried out excluding non-compliers (patients who took <80% therapy).,['0'],['12b']
PMC4515982,S98,"demographic characteristics and clinical features of randomised patients at baseline were reported by treatment arm and compared using χ2 test, student t test, wilcoxon rank-sum test or fisher’s exact test as appropriate.",['0'],['12a']
PMC4515982,S99,"time from randomisation to death, tracheotomy or >23 h niv daily for 14 consecutive days was analysed in terms of the annualised rate with the corresponding 95% ci, and p value using a χ2 test with one degree of freedom for rate comparison (based on poisson regression).",['12a'],['12a']
PMC4515982,S100,the kaplan-meier method was used to obtain survival curves with the corresponding log-rank test.,['12a'],['12a']
PMC4515982,S101,"a cox model was applied to estimate the treatment effect in terms of hr with 95% ci, adjusted for sex, age, alsfrs-r score at baseline and disease duration.",['12a'],['12b']
PMC4515982,S102,the number of patients experiencing an ae causing withdrawal were reported and compared between the two groups by kaplan-meier curves of the time to withdrawal and the corresponding log-rank test.,['12a'],['12a']
PMC4515982,S103,"change from baseline in svc, alsfrs-r and alsaq-40 was assayed by mixed effect models.",['12a'],['12a']
PMC4515982,S104,"all data were analysed using sas v.9.3 (sas institute inc. cary, north carolina, usa).",['12a'],['12a']
PMC4515982,S105,"this study is registered with eudract, number 2009-016066-91 (epos trial).",['0'],[]
PMC5064025,S44,"novartis pharmaceuticals (cambridge, massachusetts) initiated this phase ii, double-blind, randomized, placebo-controlled trial, with the final study protocol designed in collaboration with the investigators (r.p.c., j.-c.t., and z.a.f.), based on their previously published methods 19, 23, 24.",['3a'],['3a']
PMC5064025,S45,"the study was undertaken at 9 centers in canada, the united kingdom, the united states, germany, and israel, in compliance with the principles of the declaration of helsinki and according to good clinical practice guidelines.",['4b'],['4b']
PMC5064025,S46,"the protocol was reviewed and approved by the institutional review board, or equivalent, for each center.",['0'],[]
PMC5064025,S47,all participants provided written informed consent before undertaking any study procedures.,['0'],[]
PMC5064025,S49,patients (ages 18 to 74 years) were eligible for inclusion if they had clinically evident atherosclerotic vascular disease: previous myocardial infarction; history of angina; carotid stenosis (>30%); peripheral vascular disease (ankle–brachial index <0.9); endarterectomy >3 months previously; or transient ischemic attack or stroke.,['4a'],['4a']
PMC5064025,S50,"in addition, patients must also have had either t2dm (for ≤14 years and glycosylated hemoglobin [hba1c] levels between 6% and 10%) or igt (defined as a peak 2-h glucose reading ≥140 mg/dl but <200 mg/dl after an oral glucose tolerance test during screening).",['4a'],['4a']
PMC5064025,S51,patients were to have been on stable statin therapy for a period of ≥6 weeks before screening (or have physician-documented statin intolerance).,['4a'],['4a']
PMC5064025,S52,"after consent, eligible patients were randomized (1:1) to receive canakinumab 150 mg or placebo, subcutaneously, monthly for 12 months.",['5'],['5']
PMC5064025,S53,"exclusion criteria included: pregnancy; systemic steroid use; baseline high-sensitivity c-reactive protein (hs-crp) levels >30 mg/l; history of significant multiple drug allergies; history or evidence of chronic infection, including tuberculosis and liver disease; or a standard contraindication to mri.",['4a'],['4a']
PMC5064025,S54,randomization occurred between december 2009 and november 2012.,['0'],[]
PMC5064025,S55,"patient groups were assigned centrally according to a validated computer-generated randomization code, stratified according to glycemic status (t2dm or igt).","['8a', '8b', '10']",['8a']
PMC5064025,S57,an integrated vascular mri was performed at baseline and after 3 and 12 months of treatment.,['6a'],['6a']
PMC5064025,S58,"if the imaging data did not meet an evaluable standard at any time point, the patient was rescanned.",['0'],[]
PMC5064025,S59,randomization required an evaluable baseline scan.,['0'],[]
PMC5064025,S60,"the imaging procedure comprised measures of aortic wall area and distensibility, as well as carotid wall area bilaterally.",['6a'],['6a']
PMC5064025,S61,"the imaging protocol was adapted from lee et al. (19), and staff at each imaging site underwent individualized training to ensure consistency of method and data acquisition.",['0'],[]
PMC5064025,S62,"all trial sites used a 3.0-t whole-body mri scanner, including trio, tim trio, or verio (siemens medical solutions usa, inc., malvern, pennsylvania) or achieva (philips, amsterdam, the netherlands) platforms.",['6a'],[]
PMC5064025,S63,"for carotid imaging, a bilateral 4-channel carotid array (machnet b.v., roden, the netherlands) was used on the siemens scanners and an equivalent multi-channel (4 to 8) phased array carotid coil (shanghai medical, shanghai, china) was used on the philips scanners.",['6a'],['6a']
PMC5064025,S64,detailed information regarding imaging protocols and analysis is available in the online appendix.,['0'],[]
PMC5064025,S65,the velocity at which the arterial pulse propagates is termed pulsed wave velocity (pwv).,['0'],['6a']
PMC5064025,S66,"a measure of arterial stiffness, it is an independent predictor of mortality in both t2dm and igt (26).",['0'],[]
PMC5064025,S67,the sphygmocor platform (atcor medical pty.,['6a'],[]
PMC5064025,S68,"ltd., west ryde, australia) was applied immediately before mri scanning to acquire the aortic central pulse pressure from radial artery applanation tonometry and the pwv from the carotid-femoral pulse waves.",['6a'],['6a']
PMC5064025,S70,"monitoring of vital signs, electrocardiogram, standard hematology, and biochemistry (including measurement of lipoproteins, liver function, and creatine kinase) were conducted throughout the study.",['6a'],[]
PMC5064025,S71,a data monitoring committee oversaw subject safety on an ongoing basis.,['0'],[]
PMC5064025,S72,"in addition, 3 adjudication committees made blinded assessments of adverse events in relation to cardiac, malignant, and infection-related events.","['6a', '11a']","['11a', '6a']"
PMC5064025,S74,the primary efficacy objectives were the effects of the drug on aortic distensibility and total plaque burden in the aorta and carotid arteries; the primary safety objective was the safety and tolerability of canakinumab in this population.,['6a'],['6a']
PMC5064025,S75,secondary objectives included the effects of canakinumab on aortic pwv; hs-crp; hba1c; homeostasis model assessment (homa)–insulin resistance; and peak blood glucose level 2 h after an oral glucose challenge.,['6a'],['6a']
PMC5064025,S76,"exploratory analyses of peripheral biomarkers of inflammation (including il-6, serum amyloid a, and plasma lipoproteins) were also performed.",['6a'],[]
PMC5064025,S78,sample size was calculated from the study of lee et al. (19).,['0'],['7a']
PMC5064025,S79,"to detect a 35% change in aortic distensibility or an 11% change in plaque burden at 12 months to achieve a power of 0.8 and nominal p < 0.05 (2-sided), 60 patients per group were required.",['7a'],['7a']
PMC5064025,S80,"to ensure 120 datasets with 12-month follow-up data, it was planned to randomize 190 patients.",['7a'],['7a']
PMC5064025,S81,"given the exploratory nature of the study, corrections were not made for the multiplicity of statistical tests.",['12a'],[]
PMC5064025,S82,"as defined by the protocol, patients were included in the 3-month data analysis if they had no missing doses at 3 months; for the 12-month analysis, participants were required to have no missing doses by 3 months and 1 or no missing doses between 3 and 12 months.",['0'],['4a']
PMC5064025,S83,"to compare treatment with placebo, we conducted an analysis of covariance on change from baseline, including the glycemic status as a factor and the baseline as a covariate at 3 and 12 months.",['12b'],['12a']
PMC5064025,S84,"all data were checked for normality and log-transformed, if appropriate.",['12a'],['12a']
PMC5064025,S85,"when a log transformation of the change from baseline was not possible because of negative values, an analysis of covariance was conducted on the log-transformed 3- and 12-month data, including glycemic index status as a factor and the log-transformed baseline as a covariate.",['12b'],['12a']
PMC5064025,S86,we considered a p value <0.05 as significant.,['0'],[]
PMC5064025,S87,results are reported as means with 95% confidence limits.,['0'],['12a']
PMC5064025,S88,"two interim analyses were pre-specified, when n = 60 and all patients had completed 3 months of treatment, respectively, with the intention of halting the study if adverse measures were identified or for futility but not for interim positive efficacy.",['7b'],['7b']
PMC5064025,S89,the interim analyses were performed by independent personnel not directly associated with the study’s conduct.,['7b'],[]
PMC5064025,S90,the study sponsor and funder (novartis) participated in discussions about the design and conduct of this study; they also provided the drugs used in the trial and logistical support for its execution.,['0'],[]
PMC5064025,S91,"the trial design, endpoints, and statistical analyses were largely derived from the academic investigators’ previously published studies 19, 23, 24.",['0'],[]
PMC5064025,S92,"following the final database lock, all patient data were analyzed independently by the centre for statistics in medicine, oxford (j.b.).",['0'],[]
PMC5064025,S93,"the manuscript was drafted by the academic investigators (r.p.c., j.s.b., j.-c.t., and z.a.f.), in accordance with the written agreement between novartis and the academic institutions, and reviewed and revised by the writing committee.",['0'],[]
PMC5064025,S94,all authors had full access to all the data in the study and assume responsibility for publication.,['0'],[]
PMC5064025,S95,"all statistical analyses were performed by using stata 14 (statacorp lp, college station, texas).",['12a'],['12a']
PMC3018567,S46,the study is described in detail elsewhere.18,['0'],[]
PMC3018567,S47,"briefly, the study area was entebbe municipality and katabi subcounty, beside lake victoria, uganda.",['4b'],[]
PMC3018567,S48,"the area is occupied by urban, rural, and fishing communities.",['0'],[]
PMC3018567,S49,"helminth infection is highly prevalent in the area,19 and malaria, diarrhoea, and pneumonia are common in young children.20",['0'],[]
PMC3018567,S50,"the study population consisted of pregnant women who presented at the government-funded antenatal clinic at entebbe general hospital between april 9, 2003, and nov 24, 2005, where roughly 70% of pregnant women from the study area received antenatal care.21",['4b'],['4a']
PMC3018567,S51,"women were included if resident in the study area, planning to deliver in the hospital, willing to know their hiv status, and in the second or third trimester of pregnancy.",['4a'],['4a']
PMC3018567,S52,"they were excluded if they had possible helminth-induced pathological changes (haemoglobin <80 g/l, clinically apparent severe liver disease, or diarrhoea with blood in stool), a history of an adverse reaction to anthelmintics, already been enrolled in the trial during an earlier pregnancy, or if the pregnancy was deemed abnormal by a midwife.",['4a'],['4a']
PMC3018567,S53,"all participants gave written, informed consent.",['0'],[]
PMC3018567,S54,"ethics approval was given by the uganda virus research institute, uganda national council for science and technology, and london school of hygiene and tropical medicine.",['0'],[]
PMC3018567,S56,"we used a two-by-two factorial design to randomly assign patients in a 1:1:1:1 ratio to receive simultaneously either single-dose albendazole (440 mg) and single-dose praziquantel (40 mg/kg), albendazole and a praziquantel-matching placebo, an albendazole-matching placebo and praziquantel, or an albendazole-matching placebo and a praziquantel-matching placebo (albendazole and matching placebo, glaxosmithkline, brentford, uk; praziquantel and matching placebo, medochemie ltd, limassal, cyprus).","['8b', '5', '3a']",['5']
PMC3018567,S57,"the randomisation code was generated by the trial statistician with a computer-generated random number sequence, with block size 100.","['8a', '8b']",['8a']
PMC3018567,S58,treatments were packed in sealed envelopes and labelled with an allocation number by colleagues at the medical research council unit in entebbe who did not otherwise contribute to the trial.,['9'],"['10', '9']"
PMC3018567,S59,treatments were allocated in numerical order by trained interviewer-counsellors who observed the patients taking the treatment correctly on enrolment to the study.,['10'],['10']
PMC3018567,S60,treatment allocation was masked from all participants and staff during the study.,['11a'],['11a']
PMC3018567,S62,"demographic and clinical details, and blood samples were obtained at screening; stool samples were obtained before enrolment.",['0'],[]
PMC3018567,S63,"after enrolment, women continued to receive standard antenatal care, including haematinics, tetanus immunisation, and intermittent presumptive treatment for malaria twice after their first trimester of pregnancy; women with hiv were offered intrapartum and neonatal single-dose nevirapine for prevention of mother-to-child (vertical) hiv transmission.22",['5'],['5']
PMC3018567,S64,"stool samples were obtained after delivery to assess effectiveness of anthelmintic treatment; thereafter, all mothers received praziquantel and albendazole.","['5', '6a']",[]
PMC3018567,S65,"infants received bcg and polio immunisation at birth; diphtheria, pertussis, tetanus, haemophilus influenzae, hepatitis b, and polio immunisation at 6, 10, and 14 weeks; and measles immunisation at 9 months.",['5'],['5']
PMC3018567,S66,"children also attended the study clinic when unwell; doctors diagnosed, treated, and recorded their illnesses.",['0'],[]
PMC3018567,S67,"community fieldworkers visited each participant's home twice a month, measured the child's temperature, and recorded symptoms reported by the child's carer.",['6a'],['6a']
PMC3018567,S68,"at age 12 months, blood and stool samples were obtained from the children and growth outcomes were measured.",['6a'],['6a']
PMC3018567,S69,children who were unwell at their 12-month visit were given appropriate treatment and asked to return to complete the visit procedures when well.,['6a'],['5']
PMC3018567,S70,"the primary outcomes were immune response at age 1 year to bcg, tetanus, and measles immunisation; incidence of malaria, diarrhoea, pneumonia, measles, and tuberculosis during infancy as diagnosed by doctors at the study clinic; and vertical hiv transmission.18",['6a'],['6a']
PMC3018567,S71,planned secondary outcomes were growth and anaemia at age 1 year.,['6a'],['6a']
PMC3018567,S72,community-reported data for illness events were included as a secondary outcome for comparison with doctor-diagnosed illness events from clinic visits.,['6a'],['6a']
PMC3018567,S73,we also considered two additional unplanned secondary outcomes: infant mortality and asymptomatic malaria (presence of malaria parasitaemia) at 1 year of age.,['6a'],['6a']
PMC3018567,S74,cytokine responses at 1 year of age to crude culture filtrate proteins of mycobacterium tuberculosis (ccfp) were measured as an indicator of response to bcg immunisation.,['6a'],['6a']
PMC3018567,S75,cytokine responses at age 1 year to tetanus toxoid were measured as an indicator of response to tetanus immunisation.,['6a'],['6a']
PMC3018567,S76,"we examined stimulated interferon-γ (type 1), interleukin-5 (type 2), interleukin-13 (type 2), and interleukin-10 (regulatory) responses in a whole-blood assay, as previously described.23",['6a'],['6a']
PMC3018567,S77,"total serum igg, igg4, and ige responses to tetanus toxoid were measured by elisa (webappendix p 1).",['6a'],['6a']
PMC3018567,S78,"total serum measles-specific igg was measured by elisa (dade behring/siemens, eschborn, germany) according to the manufacturer's protocol.",['6a'],['6a']
PMC3018567,S79,"immunological assays were done after all samples had been obtained, in a randomised sequence (by use of a computer-generated random number sequence), to avoid confounding of secular trends with variations in assay performance.",['6a'],['6a']
PMC3018567,S80,"for the primary outcome, doctor-diagnosed illness events, clinical malaria was fever (temperature ≥37·5°c) with parasitaemia; diarrhoea was an infant's carer's definition, with stool frequency recorded;24 pneumonia was cough with difficulty in breathing, and age-specific fast breathing;25 measles was defined by standard clinical criteria and confirmed by measurement of specific antibody;26 and children with suspected tuberculosis were investigated as clinically indicated.27",['6a'],['6a']
PMC3018567,S81,"for the secondary outcome, community-reported illnesses, febrile illness was defined as measured by fieldworkers (temperature ≥37·5°c) or as reported by the child's carer; diarrhoea as reported by the carer, with stool frequency recorded; presumptive pneumonia was cough with difficulty in breathing, or age-specific fast breathing as measured by fieldworkers.",['6a'],['6a']
PMC3018567,S82,"stool samples were examined for helminth ova with the kato-katz method28 and by charcoal culture for strongyloides sterocoralis infection;29 two kato-katz slides were prepared from each sample and examined for hookworm ova within 30 mins of preparation, or examined the next day for other species.",['6a'],['6a']
PMC3018567,S83,"hookworm and schistosoma mansoni infections were classified into low, medium, and high intensities according to who guidelines.30",['6a'],['6a']
PMC3018567,S84,blood samples were examined by a modified knott's method for mansonella perstans31 and by thick film for malaria parasites.,['6a'],['6a']
PMC3018567,S85,"haemoglobin was estimated by coulter analyser (beckman coulter, nyon, switzerland).",['6a'],['6a']
PMC3018567,S86,"quality control for kato-katz analyses was provided by the vector control programme of the ministry of health, uganda, and for haematology and malaria parasitology through the uk national external quality assessment schemes.",['6a'],[]
PMC3018567,S87,mothers' hiv serology was done by rapid test algorithm.30,['6a'],['6a']
PMC3018567,S88,blood was obtained from cord and at 6 weeks of age from infants of mothers with hiv for assessment of vertical hiv transmission.,['6a'],['6a']
PMC3018567,S89,plasma and whole blood cell pellet were separated by centrifugation and stored at −80°c until assays were done.,['6a'],['6a']
PMC3018567,S90,"for detection of hiv-1 proviral dna in infants at 6 weeks, dna was extracted from stored whole blood cell pellets and amplified by nested pcr of three conserved viral regions, tat, gp41, and nef (webappendix p 1).",['6a'],['6a']
PMC3018567,S91,"for both cord and 6-week samples, plasma hiv load was measured with bayer versant branched dna assay version 3.0 (bayer, leverkusen, germany) or roche amplicor hiv-1 rna monitor test version 1.5 (roche, nj, usa).",['6a'],['6a']
PMC3018567,S92,"infants were regarded as being hiv positive if the 6-week sample had a positive dna pcr for any of the viral regions and a viral load of 1000 copies per ml or more; for four infants, only viral load data were available, so they were used to establish hiv status.",['6a'],[]
PMC3018567,S93,"viral load and dna-pcr results were concordant apart from one infant (viral load 6699 copies per ml, pcr negative) who was seronegative by rapid test algorithm at age 18 months and was classified as hiv negative.",['0'],['6a']
PMC3018567,S94,"in infants with hiv infection, transmission was regarded as likely to have been intrauterine if the viral load in cord blood was 1000 copies per ml or more.",['6a'],[]
PMC3018567,S96,analysis was done after all children were older than 15 months.,['0'],[]
PMC3018567,S97,"data for samples and measurements obtained at routine, 1-year visits were included if the child attended within 2 months after their first birthday.",['0'],[]
PMC3018567,S98,data for illness events and mortality were censored strictly at 1 year.,['0'],[]
PMC3018567,S99,results for younger twins were excluded from all analyses.,['0'],[]
PMC3018567,S100,"on the basis of our preliminary study,32 the planned cohort size of 2500 was expected to accrue 1860 person-years of follow-up in infancy and 1594 infants were expected to be seen at age 1 year.",['7a'],['7a']
PMC3018567,S101,"for either maternal treatment, assuming no interaction between treatments, this number would give 80% power to detect rate ratios of 0·82 for malaria, 0·91 for diarrhoea, and 0·76 for pneumonia, with p values of less than 0·05, assuming frequency of disease in the placebo groups to be 50 per 100 person-years for malaria,33 190 per 100 person-years for diarrhoea,34 and 25 per 100 person-years for pneumonia.35",['7a'],['7a']
PMC3018567,S102,"incidence of both tuberculosis and measles was expected to be low,18 therefore only very large differences in incidence would be detected.",['0'],[]
PMC3018567,S103,"samples from 1594 infants assessed at 1 year would detect differences in infant cytokine responses of 0·11 log10 between intervention groups.18,32",['0'],['7a']
PMC3018567,S104,the patients that were included in analysis for each of the primary outcomes differed because data for each outcome was obtained at different times.,['0'],[]
PMC3018567,S105,"for immune response at age 1 year, analysis included all children who provided a blood sample at 1 year and who had received full bcg (for ccfp analysis) or tetanus (for tetanus toxoid analysis) immunisation at entebbe hospital; second-born twins were excluded.",['0'],[]
PMC3018567,S106,"for incidence of infectious diseases during infancy, analysis included all liveborn children, excluding second-born twins.",['0'],[]
PMC3018567,S107,"for vertical hiv transmission, analysis included all children whose mothers were not receiving highly-active antiretroviral therapy, and from whom blood samples at age 6 weeks were available; second-born twins were excluded.",['0'],[]
PMC3018567,S108,"cytokine and antibody responses showed skewed distributions, with disproportionate numbers of zero values.",['0'],['12a']
PMC3018567,S109,results were transformed to log10(concentration+1) and analysed by linear regression with bootstrapping to estimate bias-corrected accelerated confidence intervals.36,['12a'],['12a']
PMC3018567,S110,regression coefficients were back-transformed to give geometric mean ratios.,['12a'],['12a']
PMC3018567,S111,interactions were examined with wald tests.,['12a'],[]
PMC3018567,S112,"for doctor-diagnosed disease incidence, time at risk began at birth and was censored at loss to follow-up, death, or age 1 year.",['0'],[]
PMC3018567,S113,"all children with known date of birth were included in the analysis until censoring, irrespective of whether they had made a clinic visit for illness.",['0'],[]
PMC3018567,S114,"for each disease, we calculated incidence rates for all events.",['12a'],[]
PMC3018567,S115,"disease episodes within 14 days of an initial presentation with the same disease were regarded as part of the same episode and excluded from the analysis; time at risk was adjusted accordingly, excluding these 14-day periods from the total person-time denominator.",['0'],[]
PMC3018567,S116,"hazard ratios (hrs) for effects of treatment were calculated with cox regression, with robust ses to allow for within-child clustering.",['12a'],['12a']
PMC3018567,S117,"for community-reported illness data, a generalised-estimating-equation approach with exchangeable correlation structure was used to model effects of treatment on repeated binary outcomes.",['12a'],['12a']
PMC3018567,S118,odds ratios (ors) for the effects of treatment on vertical hiv transmission were calculated with logistic regression.,['12a'],['12a']
PMC3018567,S119,the prevalence of asymptomatic malaria at 1 year was compared between treatment groups with logistic regression.,['12a'],['12a']
PMC3018567,S120,"infant mortality per 1000 livebirths was estimated from kaplan-meier survival probabilities to age 1 year, and effects of maternal anthelmintic treatment were assessed by cox regression.",['12a'],['12a']
PMC3018567,S121,"weight-for-age, height-for-age, and weight-for-height z scores at 1 year were derived from who growth standard reference scales, with igrowup macros.",['12a'],['6a']
PMC3018567,S122,we examined effects of maternal treatment on z scores and on haemoglobin at 1 year by linear regression.,['12a'],['12a']
PMC3018567,S123,"we did two prespecified subgroup analyses, examining effects of albendazole treatment in children of mothers with a hookworm infection, and effects of praziquantel treatment in children of mothers with schistosomiasis.",['12b'],['12b']
PMC3018567,S124,differences between subgroups were examined by fitting interaction terms in regression models.,['12b'],"['12a', '12b']"
PMC3018567,S125,all p values were two-sided with no adjustment made for multiple comparisons.,"['12a', '12b']",['12a']
PMC3018567,S126,analyses were done with stata 10.1.,['12a'],['12a']
PMC3018567,S128,"the sponsor of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report.",['0'],[]
PMC3018567,S129,ame had full access to all the data in the study and had final responsibility for the decision to submit for publication.,['0'],[]
PMC3002766,S45,"this double-blind, randomised, parallel-group, placebo-controlled study consisted of a ≤2-week screening period, a 24-week treatment period and an 8-week post-treatment follow-up period.",['3a'],['3a']
PMC3002766,S46,the study was approved by local ethics committees and conducted in accordance with the amended declaration of helsinki.,['0'],[]
PMC3002766,S47,all patients gave written informed consent.,['0'],[]
PMC3002766,S49,the study was conducted from october 2003 to may 2005 at 41 centres in europe and north america.,['4b'],['4b']
PMC3002766,S50,"recruited patients were ≥18 years old, with ssc as defined by the preliminary classification criteria of the american college of rheumatology (acr)17 and at least one active du (onset between 1 week and 3 months prior to randomisation) that was selected by the investigator and termed the ‘cardinal ulcer’ (painful area, ≥2 mm in diameter with visible depth and loss of dermis, amenable to healing and in a location judged compatible with a vascular aetiology, specified by protocol as volar surface of the digit distal to the proximal interphalangeal digital crease).",['4a'],['4a']
PMC3002766,S51,"patients were excluded if they had received intravenous prostanoids within the previous 3 months, had used phosphodiesterase inhibitors other than for intermittent treatment of male erectile dysfunction, or had received inhaled or oral prostanoids or injected botulinum toxin in an affected finger within 1 month.",['4a'],['4a']
PMC3002766,S52,patients were also excluded if they received systemic antibiotics to treat infected dus within 2 weeks prior to randomisation.,['4a'],['4a']
PMC3002766,S53,"also excluded were patients with body weight <40 kg, severe pah (who class iii/iv), moderate to severe hepatic impairment or serum aminotransferase levels >3 times the upper limit of the normal range (uln).",['4a'],['4a']
PMC3002766,S54,contraceptive measures and monthly pregnancy testing were required during and for 3 months after the end of study treatment.,['0'],[]
PMC3002766,S56,"after screening, patients were randomised to bosentan or placebo (1:1 ratio) by sequential allocation of randomisation numbers distributed to each centre in blocks of four.","['8a', '8b']","['10', '8a', '8b']"
PMC3002766,S57,patients received bosentan 62.5 mg twice daily for 4 weeks and then 125 mg twice daily for the remainder of the treatment period or matching placebo.,['5'],['5']
PMC3002766,S58,"the dose could remain at or be decreased to the starting dose due to intolerance, with possible subsequent increase to the target dose.",['5'],['5']
PMC3002766,S59,"concomitant use of systemic antibiotics, analgaesics and topical treatments for wound care were allowed, and randomised treatment was administered in addition to the usual, stable (over the previous month) treatment for raynaud's phenomenon.",['5'],['5']
PMC3002766,S60,"patients who required parenteral, oral or inhaled prostanoid treatment during the study were first discontinued from study treatment.",['5'],['5']
PMC3002766,S61,"use of glibenclamide, fluconazole, calcineurin inhibitors or ciclosporin a was not allowed due to potential drug interactions.",['5'],['5']
PMC3002766,S63,the two primary end points were (1) the mean number of new dus per patient assessed by the investigator up to week 24 and (2) the time to healing of the cardinal ulcer up to week 24 in patients with cardinal ulcer healing maintained for 12 or more weeks.,['6a'],['6a']
PMC3002766,S64,"healing was defined as complete epithelialisation, regardless of residual pain.",['6a'],['6a']
PMC3002766,S65,maintenance of cardinal ulcer healing required no recurrence at or contiguous to the original location at week 24 (if healing occurred before or at week 12) or during 12 weeks of observation with permissible extension of the treatment period (if healing occurred after week 12).,['6a'],['5']
PMC3002766,S66,"to verify that the effect of treatment would not vary substantially across relevant baseline subgroups, the number of new dus up to week 24 was additionally analysed in subgroups based on predefined baseline factors associated with disease severity.",['6a'],['12b']
PMC3002766,S67,"secondary and exploratory end points included: (1) reduction of new dus and overall du number (proportions of patients with no new dus and with each number of new dus up to week 24, time to onset of each number of new dus up to week 24 and change from baseline to week 24 in total number of all dus), (2) healing (time to healing of all baseline dus and of all new dus through week 24, and proportions of patients with healing of all dus by the end of week 24) and (3) pain and disability parameters (changes from baseline to week 24: in pain of the cardinal ulcer and overall hand pain assessed on visual analogue scales; hand disability index (an averaged score from the three health assessment questionnaire (haq) domains of dressing/grooming, grip and hygiene); and haq disability index18 19).",['6a'],['6a']
PMC3002766,S68,"post hoc analyses included: (1) the number of new dus up to week 12 in the overall patient population and in subgroups defined by randomisation month (october–february or autumn–winter and march–september or spring–summer) and (2) number of new dus, time to each successive new du and total number of dus through week 24 in subgroups defined by the number of dus at baseline (<4 and ≥4).",['6a'],['6a']
PMC3002766,S69,"patients were evaluated at randomisation/baseline and every 4 weeks during treatment (or premature withdrawal, week 24 and, if applicable, 12 weeks after healing of the cardinal ulcer), with dus assessed at each study visit.",['0'],['6a']
PMC3002766,S70,safety was continually monitored.,['0'],[]
PMC3002766,S72,"efficacy analyses were performed on all treated patients using sas software (sas institute, cary, north carolina, usa).",['12a'],['12a']
PMC3002766,S73,means±ses are presented for numerical variables and kaplan–meier estimates for time-to-event variables.,['12a'],['12a']
PMC3002766,S74,treatment effects for the primary end points were evaluated using the pitman permutation (new dus) and log-rank test with asymptotic approximation (time to healing of the cardinal ulcer).,['12a'],['12a']
PMC3002766,S75,"missing data on new dus were imputed using extrapolation, with the incidence rate of new dus at the last assessment corrected for the missing time period.",['12a'],['12a']
PMC3002766,S76,the worst of either the calculated number or observed values at week 24 was used for patients who prematurely discontinued study treatment.,['0'],[]
PMC3002766,S77,"patients with no valid assessment post baseline (three patients on bosentan, one on placebo) were excluded from the main analysis.",['0'],[]
PMC3002766,S78,treatment effects for new dus in predefined subgroups were presented as point estimates and 95% two-sided cis.,['12a'],['12a']
PMC3002766,S79,"for exploratory purposes, statistical tests of treatment difference were provided for planned secondary/exploratory and unplanned post hoc efficacy analyses and included the pitman permutation (for changes from baseline), the fisher exact test (for proportions) and the log-rank test (for times to event), each performed without correction for multiple testing.","['12a', '12b']",['12a']
PMC3002766,S80,"placebo-corrected changes from baseline, rr and hrs from cox modelling were each reported with 95% cis where appropriate.","['12a', '12b']",['12a']
PMC3002766,S81,"safety and baseline data were summarised descriptively, with no statistical testing planned or given.",['0'],['12a']
PMC4469977,S39,the trial protocol has been published previously.11,['0'],[]
PMC4469977,S41,"we carried out a multicentre, parallel group, observer blind randomised controlled trial to compare the efficacy and safety of ciclosporin with that of prednisolone.",['3a'],['3a']
PMC4469977,S42,participants gave written informed consent.,['0'],[]
PMC4469977,S43,oversight of the trial included a trial management group and independent trial steering and data monitoring committees.,['0'],[]
PMC4469977,S44,"patients suitable for topical treatment were entered into a parallel observational study, the results of which will be reported separately.",['0'],['3a']
PMC4469977,S46,patients were involved in the design and conduct of this research.,['0'],[]
PMC4469977,S47,"during the feasibility stage, priority of the research question, choice of outcome measures, and methods of recruitment were informed by discussions with patients through a focus group session and two structured interviews.",['0'],[]
PMC4469977,S48,"during the trial, a patient joined the independent trial steering committee.",['0'],[]
PMC4469977,S49,members of the uk dermatology clinical trials network also identified this research as being a priority area for clinicians treating patients with pyoderma gangrenosum.,['0'],[]
PMC4469977,S50,"once the trial has been published, participants will be informed of the results through a dedicated website (www.stopgaptrial.co.uk) and will be sent details of the results in a study newsletter suitable for a non-specialist audience.",['0'],[]
PMC4469977,S52,recruitment took place at 39 hospitals in the united kingdom.,['4b'],['4b']
PMC4469977,S53,"participants were aged 18 years or more, with a diagnosis of pyoderma gangrenosum made by a recruiting dermatologist.",['4a'],['4a']
PMC4469977,S54,"histopathology is rarely pathognomonic for pyoderma gangrenosum, and many clinicians avoid biopsy because of the risk of an immunological reaction that results in ulcer extension at the biopsy site.",['0'],[]
PMC4469977,S55,"if the clinical diagnosis was uncertain, a biopsy was performed to exclude other diagnoses such as malignancy, granulomatous pyoderma gangrenosum, and arteritis, and advice was sought from an expert panel as necessary.",['0'],['6a']
PMC4469977,S56,"we excluded patients with pustular or granulomatous variants of pyoderma gangrenosum (as they may respond differently to treatment, and measurement of a single ulcer was not possible); patients receiving oral prednisolone, ciclosporin, or intravenous immunoglobulin in the previous month; patients participating in another clinical trial; women who were pregnant, lactating, or at risk of pregnancy; patients with known hypersensitivity to either of the study treatments; patients with clinically important renal impairment or other pretreatment findings that would result in the investigator not using either of the study drugs; patients with malignant or premalignant disease; patients with a concurrent medical condition for which treatments might interfere with ongoing treatment or cause harm; and patients taking rosuvastatin or those who had received a live vaccine in the two weeks before randomisation.",['4a'],['4a']
PMC4469977,S58,participants received oral prednisolone (brand chosen according to local practice) 0.75 mg/kg/day in a single dose or ciclosporin (neoral; novartis) 4 mg/kg/day in two divided doses.,['5'],['5']
PMC4469977,S59,"as this was a pragmatic trial, the dose could be adjusted according to normal practice, to a maximum of 1 mg/kg/day for prednisolone and 5 mg/kg/day for ciclosporin.7 10",['5'],"['3a', '5']"
PMC4469977,S60,topical treatment was prohibited during the trial.,['5'],['5']
PMC4469977,S61,a change to the protocol was made in august 2011 (after 82 participants had been enrolled) as bowel perforation was experienced by a participant receiving prednisolone 110 mg/day.,['3b'],['5']
PMC4469977,S62,as a result we implemented ceiling doses of 75 mg/day for prednisolone and 400 mg/day for ciclosporin.,['3b'],['5']
PMC4469977,S64,"participants were randomised (1:1) to treatment allocation using a web based randomisation system hosted by nottingham clinical trials unit, using a computer generated pseudorandom list, with permuted blocks of randomly varying size between two and six (ralloc add-on12 for stata, tx).","['8a', '8b', '10']","['10', '8a', '8b']"
PMC4469977,S65,randomisation was stratified by target lesion size (<20 cm2; ≥20 cm2) and presence or absence of underlying systemic disease.,['8b'],['8b']
PMC4469977,S66,it was not possible to blind clinicians and participants to treatment allocation owing to resource limitations and the complexities of different dosing regimens and safety testing of the two drugs.,['11a'],['11a']
PMC4469977,S67,"as a result, clinicians and participants were informed of their treatment allocation once data had been irrevocably entered into the randomisation database.",['11a'],[]
PMC4469977,S68,"treatment allocation was concealed from the statistician and blinded assessors of the digital images until interventions were all assigned and recruitment, data collection, data cleaning, and blind analysis were complete.",['11a'],['11a']
PMC4469977,S69,assessors blind to the allocated treatment assessed the ulcer size and global treatment response from digital images of the target lesion.,['6a'],"['11a', '6a']"
PMC4469977,S70,"if digital images were not available, the assessors used physical measurements of the lesion taken during clinic visits and global response by the treating clinician.",['6a'],['6a']
PMC4469977,S72,"clinic visits took place at baseline, week 2, and week 6 (primary outcome) and when the ulcer had healed (up to a maximum of six months).",['6a'],['6a']
PMC4469977,S73,patient reported outcomes were collected from daily diaries or postal questionnaires.,['6a'],['6a']
PMC4469977,S74,"for participants whose pyoderma gangrenosum had healed, we assessed recurrence and time to recurrence from medical notes.",['6a'],['6a']
PMC4469977,S76,a template was photographed alongside the target ulcer to calibrate the image in the image analysis software (see supplementary figure).,['6a'],['6a']
PMC4469977,S77,"two trained assessors mapped the circumference of the lesion using verg videometry vev md software (vista medical, winnipeg, canada).",['6a'],['6a']
PMC4469977,S78,two dermatologists independently reviewed all images to ensure that the lesions were consistent with a diagnosis of pyoderma gangrenosum and that the measurements taken by the trained assessors were an accurate representation of the ulcer’s size.,['6a'],['6a']
PMC4469977,S81,"the main outcome measure was speed of healing over six weeks, captured for a single target lesion for each patient.",['6a'],['6a']
PMC4469977,S82,"if multiple lesions were present, we designated the largest lesion that could be photographed on a single plane as the target lesion.",['6a'],['6a']
PMC4469977,S83,"we chose speed of healing for the primary outcome as previous studies have shown it to be a good predictor of healing in patients with leg ulcers,13 14 and because blinded outcome assessment was possible using digital images and independent assessors.",['6a'],['6a']
PMC4469977,S84,assessing the primary outcome at six weeks also minimised loss to follow-up and the impact of participants switching to alternative treatments before primary outcome assessment.,['0'],[]
PMC4469977,S85,"in cases where digital images were unavailable, or of poor quality, we used physical measurements of the ulcer taken by non-blinded clinicians at baseline and six weeks.",['6a'],['6a']
PMC4469977,S87,time to healing—defined as the time at which sterile dressings were no longer required (reported by patients and confirmed by clinicians at subsequent clinic visits).,['6a'],['6a']
PMC4469977,S88,we identified this outcome as the most important of the secondary outcomes.,['6a'],[]
PMC4469977,S89,pyoderma gangrenosum specific global treatment response—to assess treatment response we used a seven point likert scale ranging from completely clear through to worse (assessed by clinicians and participants and from digital images for blinded assessment).,['6a'],['6a']
PMC4469977,S90,resolution of inflammation—this was recorded by clinicians and participants using a scale reported by foss.15,['6a'],['6a']
PMC4469977,S91,"self reported pain—participants self reported the severity of pain daily using a score from 0 to 4 (none, mild, moderate, severe, or extreme).",['6a'],['6a']
PMC4469977,S92,"health related quality of life—assessed using the dermatology life quality index16 and european quality of life-5 dimensions, three levels (eq-5d-3l and eq vas).17 18",['6a'],['6a']
PMC4469977,S93,time to recurrence—defined as the interval between the target lesion healing and a further episode of pyoderma gangrenosum (at any site).,['6a'],['6a']
PMC4469977,S94,the period of follow-up available varied depending on the time at which participants were randomised into the trial.,['6a'],[]
PMC4469977,S95,"number of treatment failures—defined as those who withdrew from their randomised treatment because of treatment intolerance, whose pyoderma gangrenosum worsened, or whose target lesion remained unhealed after six months of follow-up.",['6a'],['6a']
PMC4469977,S96,"adverse reactions to study drugs—adverse events that were possibly, probably, or definitely related to the study drug.",['6a'],[]
PMC4469977,S98,"this was a superiority trial, with prednisolone as the control intervention.",['0'],['3a']
PMC4469977,S99,"to provide 80% power (5% level of significance) to detect a difference in means of 0.5 standard deviations in the primary outcome of speed of healing over six weeks, the target sample size was 140 participants, assuming a loss to follow-up of 10%.",['7a'],['7a']
PMC4469977,S100,"we chose a difference of 0.5 standard deviations as being a clinically meaningful between group difference, as observational data suggested that ciclosporin was potentially more effective, but at higher cost, than prednisolone.19 20 21",['7a'],['7a']
PMC4469977,S101,"as a result, we felt that a substantial treatment effect was necessary to justify a change in clinical practice.",['7a'],[]
PMC4469977,S103,we prespecified all analyses in a statistical analysis plan.,['0'],['12a']
PMC4469977,S104,"analysis was conducted using intention to treat principles; defined as all randomised participants, excluding those with a later diagnosis determined to be something other than pyoderma gangrenosum.",['0'],[]
PMC4469977,S105,we included all participants with available data at both the baseline and the six week visit in the primary analysis.,['0'],[]
PMC4469977,S106,the impact of missing values was explored in sensitivity analysis.,['12a'],[]
PMC4469977,S107,"a linear regression model was used to analyse differences between treatment groups for the primary outcome at six weeks, adjusting for the stratification variables.",['12a'],[]
PMC4469977,S108,"secondary outcomes were analysed using cox regression models (for time to event outcomes); linear regression models for dermatology life quality index, eq-5d, and eq-vas (adjusted for baseline values), and for self reported pain (which were summarised using area under the curve); proportional odds models for ordered categorical outcomes; and logistic regression models for binary outcomes.",['12a'],['12a']
PMC4469977,S109,all analyses were adjusted for the stratification variables.,['0'],[]
PMC4469977,S110,"sensitivity analysis of the primary outcome and time to healing were further adjusted for additional baseline variables including age, sex, weight, size of recruiting centre and geographical region; missing data; and participants who switched randomised treatments or received the trial drugs in combination during the period of the trial.",['12b'],[]
PMC4469977,S111,"we analysed adverse reactions that occurred during the trial according to the original randomised allocation, regardless of whether other drugs had been introduced before the adverse reaction.",['0'],[]
PMC4469977,S112,"all statistical analyses were conducted using sas software, version 9.2 and r version 2.10.1.",['12a'],['12a']
PMC4770816,S36,the methods used in past-bp have been reported in detail elsewhere.14,['0'],[]
PMC4770816,S37,past-bp was an individually randomised trial in which participants were allocated to either an intensive blood pressure target (<130 mm hg or a 10 mm hg reduction if baseline pressure was <140 mm hg) or a standard target (<140 mm hg).,['3a'],['3a']
PMC4770816,S38,patients were recruited from 106 general practices (of which 99 contributed at least one patient) in england during 2009-11.,['4b'],['4b']
PMC4770816,S39,patients were considered for inclusion if they were on the practice’s tia/stroke register.,['4a'],['4a']
PMC4770816,S40,"they were excluded if their baseline systolic blood pressure was less than 125 mm hg, they were already taking three or more antihypertensive agents, they had a greater than 20 mm hg postural change in systolic blood pressure on standing, they were already being treated to a 130 mm hg systolic blood pressure target, they were unable to provide informed consent, or there was insufficient corroborative evidence that they had had a stroke or tia.",['4a'],['4a']
PMC4770816,S41,potentially eligible participants were identified using a search of the general practice’s clinical computer system.,['0'],['4a']
PMC4770816,S42,a general practitioner reviewed this list to exclude patients for whom a study invitation would be inappropriate.,['0'],['4a']
PMC4770816,S43,"the remainder were sent a letter inviting them to attend a study clinic appointment held at their general practice by a research nurse, where written informed consent was obtained.",['0'],['10']
PMC4770816,S45,"the central study team at the university of birmingham randomised patients, with minimisation based on age, sex, diabetes mellitus, atrial fibrillation, baseline systolic blood pressure, and general practice.","['10', '8b']",[]
PMC4770816,S46,the research nurse ascertained treatment allocation either by telephone or online.,['10'],['10']
PMC4770816,S47,neither participants nor clinicians were blinded to treatment allocation.,['11a'],['11a']
PMC4770816,S48,a research nurse who was not otherwise involved in the patient’s care obtained the primary outcome measure (blood pressure) by using an automated sphygmomanometer.,['6a'],['6a']
PMC4770816,S50,patients randomised to the intensive arm were given a target systolic blood pressure of below 130 mm hg or a target reduction of 10 mm hg if their baseline blood pressure was between 125 and 140 mm hg.,['5'],['5']
PMC4770816,S51,"the target in the standard arm was less than 140 mm hg, irrespective of baseline blood pressure.",['5'],['6a']
PMC4770816,S52,"apart from the different blood pressure targets, the management of blood pressure was the same in both groups and was carried out by a practice nurse (to monitor blood pressure) and a general practitioner (responsible for modifying blood pressure treatment).",['5'],['5']
PMC4770816,S53,patients whose systolic blood pressure at baseline was above target (everyone in the intensive arm and those patients in the standard arm whose blood pressure was ≥140 mm hg) had their antihypertensive treatment reviewed by their general practitioner.,['5'],['5']
PMC4770816,S54,a practice nurse would see all patients at three month intervals (if their blood pressure was below target when previously measured) or after one month (if previous blood pressure was above target) and refer to the general practitioner if the blood pressure was above target.,['5'],[]
PMC4770816,S55,"the protocol required no formal down-titration of treatment if blood pressure was below target, but general practitioners had discretion to change or reduce treatment in the light of symptoms attributable to blood pressure drugs.",['5'],['5']
PMC4770816,S56,we provided general practitioners with treatment protocols that reflected the national guidelines for blood pressure lowering in operation at the time of the trial.15,['5'],[]
PMC4770816,S57,"in both arms of the trial, the general practitioners had access to a computer based algorithm that actively suggested drugs and dosage if the participant was above target.",['5'],['10']
PMC4770816,S58,follow-up ceased if the participant had a major cardiovascular event.,['7b'],['6a']
PMC4770816,S59,the primary outcome was change in systolic blood pressure between baseline and one year.,['6a'],['6a']
PMC4770816,S60,participants had blood pressure measured by a research nurse (separate from the practice nurse’s measurements described above) at baseline and at six and 12 months.,['6a'],['6a']
PMC4770816,S61,blood pressure was measured using a british hypertension society validated automated electronic monitor supplied and validated for the study.16,['6a'],['6a']
PMC4770816,S62,"blood pressure was measured in a standardised way, with the patient seated for five minutes and then six measurements taken at one minute intervals.",['6a'],['6a']
PMC4770816,S63,the primary outcome was the average of the second and third measurements.,['6a'],['6a']
PMC4770816,S64,"secondary measures of blood pressure included diastolic blood pressure at six and 12 months, systolic blood pressure at six months, and proportion achieving target blood pressures at 12 months.",['6a'],['6a']
PMC4770816,S65,"for the systolic blood pressure, we also calculated the means of readings 2-6 and 5-6 to look for any differential effects with regard to habituation to blood pressure measurement.",['6a'],['6a']
PMC4770816,S66,we identified clinical events through review of the general practice record at 12 months.,['0'],[]
PMC4770816,S67,"these comprised major cardiovascular events (composite of fatal and non-fatal stroke, myocardial infarction, fatal coronary heart disease, or other cardiovascular death), emergency hospital admissions, and deaths.",['0'],['6a']
PMC4770816,S68,participants were flagged for mortality at the nhs central register.,['0'],[]
PMC4770816,S69,side effects were assessed through the use of standard questionnaires.14,['0'],['6a']
PMC4770816,S71,"we estimated that a sample size of 305 patients in each group would detect a 5 mm hg difference in systolic blood pressure between groups with 90% power at a significance level of 5% assuming a standard deviation of 17.5 mm hg, 10% loss to follow-up, 5% mortality, and 10% major vascular events.5 7",['7a'],['7a']
PMC4770816,S72,"we used mixed models for the primary analysis, adjusting for baseline blood pressure, age group (<80 years, ≥80 years), sex, diabetes mellitus, atrial fibrillation, and practice (as a random effect).",['12a'],"['12a', '12b']"
PMC4770816,S73,the principal analysis was a complete case analysis.,['12a'],[]
PMC4770816,S74,"we also explored the potential effects of missing values by the use of three approaches: multiple imputation, group mean, and last available value.",['12a'],['12a']
PMC4770816,S75,"subgroup analyses were pre-specified for diabetes mellitus, atrial fibrillation, and age group.",['12b'],['12b']
PMC4770816,S76,"in addition, we did a subgroup analysis by baseline systolic blood pressure (<140 mm hg, ≥140 mm hg).",['12b'],['12b']
PMC4770816,S77,"we compared the number of consultations, treatment changes, and side effects by using generalised mixed modelling, adjusting for the same variables as in the primary outcome.",['12b'],['12b']
PMC4770816,S78,"for clinical events, we calculated hazard ratios and their 95% confidence intervals by using cox proportional hazards modelling, adjusting for the same covariates mentioned previously.",['12b'],['12b']
PMC4770816,S79,we checked the proportional hazard assumption with schoenfeld residual plots and by including interaction terms in the model (for each term by time).,['12b'],['12a']
PMC4770816,S80,"for all clinical event analyses, we censored patients at the time of the first event relevant to that analysis.",['0'],[]
PMC4770816,S81,"thus, if a patient had more than one emergency hospital admission, only the first one would be counted.",['0'],[]
PMC4770816,S82,we used sas 9.2 and stata 12 for analyses.,['12a'],['12a']
PMC4770816,S84,the study was discussed by a stroke survivor group who agreed that it was an important research question and that blood pressure was an important outcome for them.,['0'],[]
PMC4770816,S85,patients were involved in developing plans for recruitment and design of the study through representation on the trial steering committee.,['0'],[]
PMC4770816,S86,no patients were asked to advise on interpretation or writing up of the results.,['0'],[]
PMC4770816,S87,we plan to disseminate the results of the research to the relevant patient community through local and nationally organised stroke groups.,['0'],[]
PMC4621368,S39,"between june 2011 and september 2013, consecutive patients referred for elective cabg surgery were recruited from two clinics at edinburgh heart centre.",['4b'],"['4a', '4b']"
PMC4621368,S40,"patients were 18 years or older, and were referred for isolated cabg surgery requiring two or more grafts.",['4a'],['4a']
PMC4621368,S41,"exclusion criteria included patients with recent myocardial infarction (within 1 month of surgery), emergency or concomitant valve surgery, significant renal impairment (estimated glomerular filtration rate<40 ml/min), severe respiratory disease (maintenance corticosteroid therapy or forced expiratory volume in 1 s <50% predicted), severe lv impairment (ef <40%), contraindication to magnetic resonance scanning, treatment for chronic inflammatory disease, women of childbearing potential and inability to provide consent.",['4a'],['4a']
PMC4621368,S43,"intravenous recombinant human elafin (proteo biotech ag, germany) 200 mg or saline placebo was prepared and infused as aqueous solution of 250 ml 0.9% saline.",['5'],['5']
PMC4621368,S44,patients were randomised (1:1) to receive elafin or matched placebo by edinburgh clinical trials unit to ensure allocation concealment.,"['8b', '10', '9']",[]
PMC4621368,S45,"randomisation incorporated minimisation for age, presence of diabetes mellitus, extent of coronary artery disease, renal function and surgeon a or b. to ensure blinding, study drugs were prepared by staff independent of the study investigators or clinical team responsible for the patient’s care.","['11a', '8b']",['11a']
PMC4621368,S46,intravenous elafin 200 mg causes complete inhibition of plasma elastase activity for 2 h and >50% inhibition for 6 h.,['0'],[]
PMC4621368,S47,this dosage regimen was selected to cover the increased elastase release following cabg surgery that peaks at the time of weaning from cardiopulmonary bypass and has returned to baseline by 6–7 h.,['5'],['5']
PMC4621368,S48,the study drug was administered to the patient through a central venous cannula over a period of 30 min. the intravenous infusion was started at first skin incision and completed at least 20 min before cardiopulmonary bypass commenced.,['5'],['5']
PMC4621368,S50,general anaesthesia was maintained with isoflurane and propofol infusion during bypass.,['0'],['5']
PMC4621368,S51,surgical approach was via a median sternotomy and cardiopulmonary bypass was started after heparin administration with a non-pulsatile flow and a membrane oxygenator.,['0'],['5']
PMC4621368,S52,"cardioprotection was provided by cold blood cardioplegia (1:4), which was administered antegradely, after cross-clamping the aorta, into the coronary arteries or by cross-clamp fibrillation.",['0'],[]
PMC4621368,S54,"blood samples were taken at baseline (time 0, skin incision) and at 2, 6, 24 and 48 h postoperatively.",['6a'],['6a']
PMC4621368,S55,"plasma cardiac troponin i (ctni) concentrations were measured with the architectstat troponin i assay and architectstat high-sensitive troponin i assay (abbott laboratories, abbott park, illinois, usa) validated in our institution.16 17",['6a'],['6a']
PMC4621368,S56,"plasma concentrations of high-sensitive c reactive protein, il-6, il-8, myeloperoxidase and elastase were quantified using elisas (r&d systems, uk; elastase elisa, cambridge biosciences, uk).",['6a'],['6a']
PMC4621368,S57,"plasma elastase activity and serum elafin concentrations were measured by the department of dermatology, university of kiel, germany.",['6a'],['6a']
PMC4621368,S59,each patient underwent cardiac mri twice: within 6 weeks before surgery and from 5 days after surgery.,['6a'],[]
PMC4621368,S60,"patients were scanned using a research-dedicated 3t siemens verio scanner (siemens medical, germany).",['6a'],['6a']
PMC4621368,S61,"quantification of lv mass, ef and late gadolinium enhancement infarct size were determined using established protocols and dedicated cardiac analysis software by two trained independent blinded observers.",['6a'],['6a']
PMC4621368,S63,the primary outcome variable was the 48 h area under the curve (auc) for plasma ctni concentration.,['6a'],['6a']
PMC4621368,S64,"it was analysed using a generalised linear model, including terms for the treatment allocation and the variables on which the randomisation was minimised.",['12a'],['12a']
PMC4621368,S65,"log transformations were applied as the data were skewed, and the results have been unlogged and presented as geometric means.",['12a'],['12a']
PMC4621368,S66,"secondary outcome measures involving the auc (hs-crp, il-6, il-8, myeloperoxidase and elastase) were analysed similarly, taking log transformation if the data were skewed.",['6a'],['12a']
PMC4621368,S67,"lvef and mass were analysed using qmass software (medis medical imaging systems, the netherlands).",['12a'],[]
PMC4621368,S68,"the change in volume of infarction from preoperative and first postoperative magnetic resonance scans was categorised as increased, no change or reduced according to detection threshold based on interobserver variability.",['12a'],['6a']
PMC4621368,S69,post hoc analyses of individual time points used wilcoxon tests.,['12a'],['12a']
PMC4621368,S70,the primary analysis included all randomised patients on an intention-to-treat basis regardless of compliance with allocated treatment and post-randomisation events.,['0'],[]
PMC4621368,S71,"a secondary pre-specified exploratory analysis of auc ctni release excluded patients who had myocardial infarction or a cardiac arrest, resulting in loss of cardiac output for >1 min. type v myocardial infarction was defined according to the third universal definition.18",['6a'],['4a']
PMC4621368,S72,"finally, post hoc, we examined treatment effect for each time point using the high-sensitive ctni assay.",['6a'],['6a']
PMC4621368,S73,power calculations were based on a recent study of patients undergoing remote ischaemic preconditioning before coronary artery bypass surgery.5,['7a'],['7a']
PMC4621368,S74,"mean cardiac troponin t release quantified as auc was 36.12 µg/l (sd 26.08) and 20.58 µg/l (sd 9.58) in the control and treated patients, respectively.",['7a'],['6a']
PMC4621368,S75,"no contemporary auc data were available for ctni release in this patient group, but the measurements are equivalent in terms of quantifying myocardial injury.",['7a'],[]
PMC4621368,S76,"with a sample size of 80 patients, we had 90% power to detect this 40% difference in auc ctni with a significance level of 5%, using a t test with unequal variances and allowing for four dropouts in each arm.",['7a'],['7a']
PMC4145439,S40,"this was a 12-week, phase iib, dose-ranging, double-blind, placebo (pbo) and active-controlled, multicenter, randomised study (nct01242488), conducted between november 2010 and june 2012, to evaluate the efficacy and safety of subcutaneous okz in patients with moderately to severely active ra who had previously failed tnf inhibitor therapy.","['3a', '4a']",['3a']
PMC4145439,S41,the study protocol was approved by the institutional review board/independent ethics committee as defined in local regulations and performed according to the declaration of helsinki.,['0'],[]
PMC4145439,S42,all patients provided written consent.,['0'],[]
PMC4145439,S43,the primary objective of the study was to evaluate the efficacy of okz at different doses and administration frequencies compared with pbo.,['6a'],['6a']
PMC4145439,S44,"secondary objectives were to evaluate the safety, pharmacokinetics (pk), pharmacodynamics (pd) and immunogenicity of repeated doses of okz, and to assess the dose-response and exposure-response relationship of okz with efficacy.",['6a'],['6a']
PMC4145439,S45,an exploratory endpoint was to compare the efficacy and safety of okz with tcz.,['6a'],['6a']
PMC4145439,S46,"of the 398 patients enrolled in the study, 221 were randomised to 1 of 9 treatment arms (figure 1).",['0'],['3a']
PMC4145439,S47,randomisation was performed centrally using an interactive voice-response system.,"['10', '8a']","['10', '8a']"
PMC4145439,S48,"patients received either pbo or okz (60, 120 or 240 mg) every 4 weeks (q4w) or every 2 weeks (q2w), or 8 mg/kg tcz q4w.",['5'],['5']
PMC4145439,S49,"doses were selected in order to cover 35–75% of the maximal anticipated effect on das28(erythrocyte sedimentation rate, esr) at 12 weeks, or 45–85% of the maximal anticipated effect at 24 weeks, based on pk/pd analysis of previous study data.19 20",['5'],['5']
PMC4145439,S50,figure 1 patient disposition.,['0'],[]
PMC4145439,S51,randomisation was stratified according to the number of prior failed tnf inhibitors (1 vs 2 or more).,['8b'],['8b']
PMC4145439,S52,two safety follow-up visits were undertaken 6 and 12 weeks after the last study dose.,['0'],['6a']
PMC4145439,S53,"to maintain blinding of the treatment, all patients received an intravenous infusion q4w and two 1.2 ml subcutaneous injections q2w.",['11a'],"['11a', '5']"
PMC4145439,S54,"tcz dose is the approved dose in europe by the ema,21 and the highest dose approved by the us food and drug administration (fda).18",['0'],[]
PMC4145439,S55,patients who completed the study were eligible to receive okz in an open-label extension study (nct01296711).,['0'],[]
PMC4145439,S57,"this study population were individuals with active ra and an inadequate response to mtx, and at least one previous anti-tnf therapy.",['4a'],['4a']
PMC4145439,S58,"patients were ≥18 years old, with adult-onset ra of at least 6 months duration (1987 american college of rheumatology (acr) classification criteria22) or a score of ≥6 by the acr/european league against rheumatism (eular) classification and diagnostic criteria for ra.23",['4a'],['4a']
PMC4145439,S59,"eligible patients had tender joint count ≥6 (tjc; assessment of 68 joints) and swollen joint count ≥6 (sjc; assessment of 66 joints) and crp ≥1.2 times the upper limit of normal (uln), or esr >28 mm/h.",['4a'],['4a']
PMC4145439,S60,patients were required to be on a stable dose of mtx and continued current steroids and nsaids.,['4a'],['4a']
PMC4145439,S61,"major exclusion criteria included diagnoses of other inflammatory arthritis or a non-inflammatory type of arthritis that interfered with efficacy evaluations, functional capacity steinbrocker class iv,24 and prior exposure to il-6 inhibitors.",['4a'],['4a']
PMC4145439,S62,patients were not permitted to use dmards other than mtx within 12 weeks prior to screening (unless undertaking appropriate washout).,['4a'],['5']
PMC4145439,S63,"patients with a known risk of severe or major infections, or elevated levels at screening of creatinine, alanine aminotransferase (alt) or aspartate aminotransferase (ast), or reduced platelets, white blood cell count or neutrophil count were excluded.",['4a'],['4a']
PMC4145439,S65,"efficacy outcomes were assessed in the full analysis set (fas), consisting of all randomised patients who received at least one dose of study medication and had at least one post-baseline efficacy measurement.",['6a'],[]
PMC4145439,S66,the primary efficacy endpoint was the change from baseline in das28(crp) at week 12.,['6a'],['6a']
PMC4145439,S67,"secondary efficacy endpoints were acr20, acr50 and acr70 at week 12 for okz and pbo.",['6a'],['6a']
PMC4145439,S68,"major exploratory analyses included: acr20/50/70 response rates (at weeks 1, 2, 4, 6, 8, 10 and 12), % of patients with das28(crp) <2.6 at weeks 2, 4, 8 and 12), tjc, sjc, clinical disease activity index (cdai) and the health assessment questionnaire-disability index (haq-di).",['6a'],['6a']
PMC4145439,S70,safety assessments included measurement of vital signs and laboratory parameters as well as recording of treatment-emergent adverse events (teaes) and serious teaes.,['6a'],['6a']
PMC4145439,S71,"safety variables were analysed using the safety set (ss) (all patients who received at least 1 dose, or partial dose, of study medication).",['0'],[]
PMC4145439,S73,"unless specifically stated, fas was used for all analyses.",['0'],[]
PMC4145439,S74,das28(crp) was analysed using a mixed effects model for repeated measures (mmrm).,['12a'],['12a']
PMC4145439,S75,acr20/50/70 responder rates were estimated using generalised estimating equation (gee) methodology with multiple imputation (mi).,['12b'],['12a']
PMC4145439,S76,missing data for sjc/tjc/haq-di/cdai change from baseline were imputed using last observation carried forward (locf).,['12b'],['12a']
PMC4145439,S77,non-responder imputation was used for analysis of % patients with das28(crp) <2.6 to control for missing values.,['12b'],[]
PMC4145439,S78,the number of prior failed tnf inhibitors was included as a categorical covariate in all statistical analyses.,['0'],['12a']
PMC4145439,S79,"unless otherwise stated, all statistical tests were two-sided.","['12a', '12b']",['12a']
PMC4145439,S80,"power and sample size calculations were based upon simulations for change from baseline in das28 at all assessed postbaseline visits, using the mmrm method specified for the primary efficacy analysis.",['7a'],['7a']
PMC4145439,S82,"blood samples for determination of plasma okz, tcz and anti-okz antibodies were collected at baseline and at each subsequent visit.",['0'],['6a']
PMC4145439,S83,non-linear mixed modelling was employed for the analysis of the okz pk data.,['12b'],['12a']
PMC4145439,S84,the final population pk model was used to derive individual concentration or exposure measures for use in the pk/pd analyses which involved describing the relationship between pk measures and multiple efficacy and safety endpoints via mixed effects methodology.,['12b'],['12a']
PMC4145439,S196,web supplement,['0'],[]
